Chimeric anti-platelet therapy (abciximab) in unstable angina refractory to standard medical therapy trial (CAPTURE)

Trial Profile

Chimeric anti-platelet therapy (abciximab) in unstable angina refractory to standard medical therapy trial (CAPTURE)

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2007

At a glance

  • Drugs Abciximab (Primary)
  • Indications Embolism and thrombosis; Unstable angina pectoris
  • Focus Registrational; Therapeutic Use
  • Acronyms CAPTURE
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 01 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top